| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocytes, Cardiac | 20 | 2024 | 618 | 4.520 |
Why?
|
| Heart | 11 | 2023 | 725 | 2.400 |
Why?
|
| Myocardium | 12 | 2023 | 983 | 2.320 |
Why?
|
| Human Embryonic Stem Cells | 4 | 2022 | 23 | 2.200 |
Why?
|
| Cellular Reprogramming | 3 | 2023 | 116 | 2.160 |
Why?
|
| Myocardial Infarction | 9 | 2023 | 996 | 1.830 |
Why?
|
| Pluripotent Stem Cells | 6 | 2021 | 76 | 1.650 |
Why?
|
| Pericytes | 2 | 2023 | 23 | 1.640 |
Why?
|
| Cell Differentiation | 17 | 2022 | 1934 | 1.550 |
Why?
|
| Stem Cell Transplantation | 5 | 2023 | 239 | 1.550 |
Why?
|
| Embryonic Stem Cells | 6 | 2018 | 172 | 1.440 |
Why?
|
| Cell Lineage | 7 | 2021 | 348 | 1.220 |
Why?
|
| Regeneration | 5 | 2023 | 202 | 1.190 |
Why?
|
| Regenerative Medicine | 3 | 2023 | 30 | 1.030 |
Why?
|
| Coronary Aneurysm | 2 | 2018 | 33 | 0.860 |
Why?
|
| Fibroblasts | 5 | 2023 | 882 | 0.840 |
Why?
|
| Cell Separation | 2 | 2021 | 237 | 0.790 |
Why?
|
| Heart Diseases | 2 | 2023 | 479 | 0.780 |
Why?
|
| Heart Injuries | 2 | 2018 | 46 | 0.740 |
Why?
|
| Integrases | 2 | 2019 | 162 | 0.730 |
Why?
|
| Cell Proliferation | 9 | 2023 | 2315 | 0.730 |
Why?
|
| Animals | 35 | 2024 | 33891 | 0.710 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2022 | 192 | 0.710 |
Why?
|
| Mesoderm | 3 | 2016 | 116 | 0.710 |
Why?
|
| Mice | 21 | 2023 | 17637 | 0.690 |
Why?
|
| Biocompatible Materials | 6 | 2022 | 124 | 0.690 |
Why?
|
| Antigens, Differentiation | 2 | 2017 | 63 | 0.680 |
Why?
|
| Recombination, Genetic | 2 | 2019 | 446 | 0.680 |
Why?
|
| Myoblasts, Cardiac | 2 | 2018 | 7 | 0.680 |
Why?
|
| Fibrosis | 5 | 2023 | 429 | 0.670 |
Why?
|
| Genes, Reporter | 1 | 2021 | 385 | 0.670 |
Why?
|
| Aortic Valve Stenosis | 2 | 2014 | 322 | 0.660 |
Why?
|
| Coronary Vessels | 4 | 2018 | 525 | 0.650 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2018 | 2 | 0.640 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 1803 | 0.620 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 2 | 2016 | 36 | 0.620 |
Why?
|
| Transcriptome | 2 | 2021 | 906 | 0.600 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2018 | 14 | 0.590 |
Why?
|
| Coronary Artery Bypass | 3 | 2018 | 486 | 0.580 |
Why?
|
| Homeobox Protein Nkx-2.5 | 1 | 2017 | 16 | 0.580 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2018 | 73 | 0.570 |
Why?
|
| Endothelial Cells | 6 | 2022 | 528 | 0.560 |
Why?
|
| Gene Targeting | 1 | 2017 | 183 | 0.540 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 354 | 0.540 |
Why?
|
| Nanoparticles | 1 | 2019 | 232 | 0.540 |
Why?
|
| Genetic Engineering | 1 | 2017 | 159 | 0.540 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2020 | 121 | 0.540 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 166 | 0.530 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2018 | 152 | 0.530 |
Why?
|
| CD13 Antigens | 1 | 2016 | 15 | 0.530 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 210 | 0.520 |
Why?
|
| Cell Tracking | 1 | 2015 | 17 | 0.520 |
Why?
|
| Ferrosoferric Oxide | 1 | 2015 | 26 | 0.500 |
Why?
|
| Bacterial Adhesion | 3 | 2003 | 108 | 0.500 |
Why?
|
| Heart Failure | 3 | 2023 | 2125 | 0.470 |
Why?
|
| Arteriosclerosis | 1 | 2014 | 139 | 0.460 |
Why?
|
| Parabiosis | 1 | 2013 | 3 | 0.450 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2015 | 155 | 0.450 |
Why?
|
| Coronary Stenosis | 1 | 2014 | 70 | 0.450 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 481 | 0.450 |
Why?
|
| Humans | 50 | 2023 | 122409 | 0.440 |
Why?
|
| Apoproteins | 2 | 2003 | 20 | 0.430 |
Why?
|
| Macrophages | 3 | 2022 | 616 | 0.420 |
Why?
|
| Transferrin | 2 | 2003 | 51 | 0.420 |
Why?
|
| Staphylococcus epidermidis | 2 | 2003 | 41 | 0.420 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 561 | 0.410 |
Why?
|
| Mice, Transgenic | 6 | 2023 | 2442 | 0.410 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2015 | 457 | 0.390 |
Why?
|
| Genetic Variation | 1 | 2018 | 1476 | 0.390 |
Why?
|
| Aortic Valve | 1 | 2014 | 426 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 174 | 0.350 |
Why?
|
| Aortic Diseases | 1 | 2012 | 197 | 0.340 |
Why?
|
| Myocytes, Smooth Muscle | 3 | 2017 | 160 | 0.340 |
Why?
|
| Fetus | 1 | 2013 | 579 | 0.330 |
Why?
|
| Tissue Engineering | 2 | 2022 | 178 | 0.320 |
Why?
|
| Epigenesis, Genetic | 2 | 2023 | 665 | 0.310 |
Why?
|
| Heart Transplantation | 3 | 2020 | 854 | 0.310 |
Why?
|
| DNA Methylation | 3 | 2023 | 991 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2012 | 711 | 0.290 |
Why?
|
| Leiomyosarcoma | 1 | 2006 | 30 | 0.270 |
Why?
|
| Cells, Cultured | 6 | 2024 | 3076 | 0.270 |
Why?
|
| Polyurethanes | 2 | 2003 | 18 | 0.270 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2006 | 65 | 0.260 |
Why?
|
| Coronary Angiography | 4 | 2018 | 417 | 0.260 |
Why?
|
| Pericardium | 2 | 2018 | 83 | 0.250 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2018 | 353 | 0.250 |
Why?
|
| Heart Neoplasms | 1 | 2006 | 103 | 0.250 |
Why?
|
| Graft Rejection | 2 | 2020 | 580 | 0.250 |
Why?
|
| MicroRNAs | 2 | 2023 | 837 | 0.250 |
Why?
|
| Mammals | 2 | 2023 | 263 | 0.250 |
Why?
|
| Uterine Neoplasms | 1 | 2006 | 119 | 0.250 |
Why?
|
| Atherosclerosis | 1 | 2012 | 828 | 0.240 |
Why?
|
| Transgenes | 2 | 2017 | 336 | 0.240 |
Why?
|
| Animals, Newborn | 3 | 2018 | 1007 | 0.240 |
Why?
|
| Zebrafish | 2 | 2018 | 379 | 0.230 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 570 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3455 | 0.230 |
Why?
|
| Female | 20 | 2022 | 64937 | 0.230 |
Why?
|
| Coronary Artery Disease | 2 | 2008 | 743 | 0.230 |
Why?
|
| Cell Culture Techniques | 3 | 2020 | 288 | 0.220 |
Why?
|
| Cell Transdifferentiation | 1 | 2023 | 67 | 0.210 |
Why?
|
| Electric Conductivity | 2 | 2022 | 89 | 0.210 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 366 | 0.210 |
Why?
|
| Green Fluorescent Proteins | 2 | 2014 | 392 | 0.210 |
Why?
|
| Stem Cells | 2 | 2020 | 710 | 0.200 |
Why?
|
| Nanotubes, Carbon | 1 | 2022 | 17 | 0.200 |
Why?
|
| Ventricular Remodeling | 1 | 2023 | 175 | 0.200 |
Why?
|
| RNA Splicing | 1 | 2023 | 223 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2007 | 2035 | 0.200 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2008 | 172 | 0.200 |
Why?
|
| Trophoblasts | 2 | 2013 | 109 | 0.200 |
Why?
|
| Extracellular Matrix | 1 | 2023 | 232 | 0.200 |
Why?
|
| Tunica Intima | 1 | 2022 | 59 | 0.190 |
Why?
|
| Thrombin | 1 | 2022 | 60 | 0.190 |
Why?
|
| Cell Line | 4 | 2016 | 2787 | 0.190 |
Why?
|
| Fibrin | 1 | 2022 | 67 | 0.190 |
Why?
|
| Myocardial Ischemia | 2 | 2015 | 330 | 0.190 |
Why?
|
| Male | 17 | 2021 | 59575 | 0.190 |
Why?
|
| Antibodies | 2 | 2020 | 371 | 0.190 |
Why?
|
| Disease Models, Animal | 3 | 2022 | 4310 | 0.190 |
Why?
|
| Signal Transduction | 4 | 2023 | 4514 | 0.180 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2002 | 163 | 0.180 |
Why?
|
| Clone Cells | 1 | 2021 | 167 | 0.180 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 45 | 0.180 |
Why?
|
| Cell Adhesion Molecules | 1 | 2021 | 226 | 0.170 |
Why?
|
| Collagen | 1 | 2021 | 312 | 0.170 |
Why?
|
| Thrombosis | 2 | 2022 | 517 | 0.170 |
Why?
|
| Endothelium, Vascular | 2 | 2013 | 514 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 1674 | 0.160 |
Why?
|
| Environmental Exposure | 1 | 2021 | 217 | 0.160 |
Why?
|
| Nanostructures | 1 | 2019 | 52 | 0.160 |
Why?
|
| Action Potentials | 1 | 2022 | 499 | 0.160 |
Why?
|
| Aorta | 2 | 2022 | 534 | 0.160 |
Why?
|
| Mice, Inbred C3H | 1 | 2018 | 119 | 0.160 |
Why?
|
| Intravital Microscopy | 1 | 2018 | 17 | 0.160 |
Why?
|
| Staphylococcus aureus | 1 | 2002 | 457 | 0.160 |
Why?
|
| Phenotype | 2 | 2018 | 4217 | 0.160 |
Why?
|
| Isoproterenol | 1 | 2018 | 106 | 0.150 |
Why?
|
| Renin-Angiotensin System | 1 | 2019 | 95 | 0.150 |
Why?
|
| Outpatients | 1 | 2020 | 254 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 371 | 0.150 |
Why?
|
| Comorbidity | 2 | 2014 | 1488 | 0.150 |
Why?
|
| Intraoperative Period | 1 | 2018 | 73 | 0.150 |
Why?
|
| Wound Healing | 1 | 2022 | 454 | 0.150 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 181 | 0.150 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2016 | 462 | 0.150 |
Why?
|
| Respiratory System | 1 | 2018 | 96 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 103 | 0.150 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 541 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2018 | 73 | 0.150 |
Why?
|
| Species Specificity | 1 | 2018 | 552 | 0.150 |
Why?
|
| Echocardiography | 3 | 2021 | 1067 | 0.150 |
Why?
|
| Social Norms | 1 | 2017 | 6 | 0.150 |
Why?
|
| Investments | 1 | 2017 | 12 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 4 | 2022 | 4383 | 0.140 |
Why?
|
| Tamoxifen | 1 | 2019 | 363 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 4 | 2021 | 331 | 0.140 |
Why?
|
| Fetal Heart | 1 | 2018 | 111 | 0.140 |
Why?
|
| Gene Silencing | 2 | 2016 | 236 | 0.140 |
Why?
|
| Angiography | 1 | 2018 | 214 | 0.140 |
Why?
|
| Disease Progression | 2 | 2014 | 1994 | 0.140 |
Why?
|
| Heart Ventricles | 1 | 2022 | 767 | 0.140 |
Why?
|
| Luminescent Proteins | 1 | 2017 | 157 | 0.140 |
Why?
|
| Monocytes | 1 | 2019 | 348 | 0.140 |
Why?
|
| X Chromosome Inactivation | 1 | 2016 | 63 | 0.140 |
Why?
|
| Aging | 3 | 2023 | 1163 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 289 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 1622 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2019 | 3306 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 1301 | 0.130 |
Why?
|
| Cell Division | 2 | 2014 | 795 | 0.130 |
Why?
|
| Ferric Compounds | 1 | 2015 | 37 | 0.130 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 137 | 0.130 |
Why?
|
| Transplantation, Heterologous | 1 | 2016 | 257 | 0.120 |
Why?
|
| Heterografts | 1 | 2015 | 184 | 0.120 |
Why?
|
| American Heart Association | 1 | 2017 | 292 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 2813 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2018 | 311 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 361 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.120 |
Why?
|
| Adult | 7 | 2023 | 28743 | 0.120 |
Why?
|
| Advisory Committees | 1 | 2015 | 148 | 0.120 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 63 | 0.110 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 107 | 0.110 |
Why?
|
| Biopsy | 1 | 2018 | 1251 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 646 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 28 | 0.110 |
Why?
|
| Polymers | 3 | 2022 | 106 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2014 | 285 | 0.110 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 110 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2023 | 2590 | 0.110 |
Why?
|
| DNA | 1 | 2019 | 1608 | 0.110 |
Why?
|
| Ear, Inner | 1 | 2013 | 52 | 0.110 |
Why?
|
| Age Distribution | 1 | 2014 | 400 | 0.110 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2013 | 80 | 0.110 |
Why?
|
| Radiography | 1 | 2015 | 807 | 0.110 |
Why?
|
| Primitive Streak | 1 | 2013 | 2 | 0.110 |
Why?
|
| Tissue Survival | 1 | 2013 | 8 | 0.110 |
Why?
|
| Indium Radioisotopes | 1 | 1993 | 10 | 0.110 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2014 | 241 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2013 | 22 | 0.110 |
Why?
|
| Multipotent Stem Cells | 1 | 2013 | 29 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 66 | 0.110 |
Why?
|
| Cardiovascular System | 1 | 2014 | 98 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2014 | 1472 | 0.100 |
Why?
|
| Flow Cytometry | 4 | 2021 | 810 | 0.100 |
Why?
|
| Endoderm | 1 | 2012 | 26 | 0.100 |
Why?
|
| Swine | 1 | 2016 | 1159 | 0.100 |
Why?
|
| Mosaicism | 1 | 2014 | 241 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2021 | 1022 | 0.100 |
Why?
|
| Middle Aged | 7 | 2020 | 25586 | 0.100 |
Why?
|
| Stage-Specific Embryonic Antigens | 1 | 2011 | 2 | 0.100 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 216 | 0.100 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2012 | 104 | 0.100 |
Why?
|
| Biomarkers | 4 | 2013 | 2942 | 0.100 |
Why?
|
| Cattle | 2 | 2003 | 558 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2017 | 510 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2013 | 1006 | 0.100 |
Why?
|
| Genes, bcl-2 | 1 | 2011 | 11 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2018 | 994 | 0.090 |
Why?
|
| Pregnancy | 3 | 2022 | 7101 | 0.090 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 54 | 0.090 |
Why?
|
| Serum | 1 | 2011 | 45 | 0.090 |
Why?
|
| Wnt Proteins | 1 | 2012 | 201 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2012 | 208 | 0.090 |
Why?
|
| Polysaccharides | 1 | 2011 | 142 | 0.090 |
Why?
|
| Teratoma | 1 | 2011 | 125 | 0.090 |
Why?
|
| Brain | 1 | 2021 | 2947 | 0.080 |
Why?
|
| Cardiology | 1 | 2015 | 468 | 0.080 |
Why?
|
| Placenta | 1 | 2013 | 490 | 0.080 |
Why?
|
| Alleles | 1 | 2014 | 1594 | 0.080 |
Why?
|
| Prognosis | 2 | 2019 | 4492 | 0.080 |
Why?
|
| Algorithms | 1 | 2016 | 1577 | 0.080 |
Why?
|
| Stress, Physiological | 1 | 2011 | 264 | 0.080 |
Why?
|
| Cell Survival | 1 | 2011 | 816 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2020 | 2998 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2020 | 12036 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 3073 | 0.070 |
Why?
|
| Prevalence | 1 | 2014 | 2369 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2012 | 839 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2012 | 1165 | 0.070 |
Why?
|
| Time Factors | 2 | 2016 | 6176 | 0.070 |
Why?
|
| Embolism, Paradoxical | 1 | 2006 | 4 | 0.070 |
Why?
|
| Embolectomy | 1 | 2006 | 9 | 0.070 |
Why?
|
| Coronary Restenosis | 1 | 2006 | 20 | 0.070 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 42 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2006 | 28 | 0.070 |
Why?
|
| Models, Animal | 2 | 2018 | 466 | 0.070 |
Why?
|
| Systole | 1 | 2006 | 197 | 0.070 |
Why?
|
| Drug Resistance, Multiple | 1 | 2006 | 50 | 0.070 |
Why?
|
| Cardiovascular Agents | 1 | 2006 | 86 | 0.060 |
Why?
|
| Aged | 5 | 2020 | 18777 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 1022 | 0.060 |
Why?
|
| Calcinosis | 1 | 2006 | 167 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 285 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2021 | 15878 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 2752 | 0.060 |
Why?
|
| Aspirin | 1 | 2006 | 222 | 0.060 |
Why?
|
| Mutation | 1 | 2018 | 5786 | 0.060 |
Why?
|
| Young Adult | 1 | 2018 | 8805 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2006 | 256 | 0.060 |
Why?
|
| Biosensing Techniques | 1 | 2024 | 50 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2007 | 631 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 548 | 0.060 |
Why?
|
| Immunoelectrophoresis | 1 | 2003 | 11 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2014 | 5970 | 0.060 |
Why?
|
| Depression, Chemical | 1 | 2003 | 43 | 0.060 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2003 | 68 | 0.060 |
Why?
|
| RNA Splicing Factors | 1 | 2023 | 49 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2004 | 194 | 0.050 |
Why?
|
| Heart Valve Diseases | 1 | 2004 | 167 | 0.050 |
Why?
|
| United States | 2 | 2017 | 10475 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 4984 | 0.050 |
Why?
|
| Video Recording | 1 | 2024 | 181 | 0.050 |
Why?
|
| Pandemics | 2 | 2020 | 1103 | 0.050 |
Why?
|
| Polystyrenes | 1 | 2002 | 14 | 0.050 |
Why?
|
| Mesonephros | 1 | 2022 | 2 | 0.050 |
Why?
|
| Recurrence | 1 | 2006 | 1412 | 0.050 |
Why?
|
| Polymethyl Methacrylate | 1 | 2002 | 23 | 0.050 |
Why?
|
| Silicones | 1 | 2002 | 33 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 2006 | 632 | 0.050 |
Why?
|
| Longevity | 1 | 2023 | 120 | 0.050 |
Why?
|
| Calcium | 1 | 2007 | 1096 | 0.050 |
Why?
|
| Equipment Design | 1 | 2024 | 598 | 0.050 |
Why?
|
| Endothelium | 1 | 2022 | 73 | 0.050 |
Why?
|
| Hydrogels | 1 | 2022 | 77 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2023 | 200 | 0.050 |
Why?
|
| Blotting, Southern | 1 | 2021 | 217 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2023 | 346 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2022 | 212 | 0.050 |
Why?
|
| Ductus Arteriosus | 1 | 2022 | 64 | 0.050 |
Why?
|
| Phylogeny | 1 | 2023 | 684 | 0.050 |
Why?
|
| Prosthesis-Related Infections | 1 | 2003 | 176 | 0.050 |
Why?
|
| Immunity | 1 | 2022 | 184 | 0.050 |
Why?
|
| Primates | 1 | 2021 | 80 | 0.050 |
Why?
|
| Los Angeles | 1 | 2020 | 18 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 968 | 0.050 |
Why?
|
| Pyrroles | 1 | 2022 | 177 | 0.040 |
Why?
|
| Genome | 1 | 2023 | 471 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 516 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2020 | 53 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2022 | 220 | 0.040 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2004 | 425 | 0.040 |
Why?
|
| Stents | 1 | 2006 | 864 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1250 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 186 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2019 | 26 | 0.040 |
Why?
|
| Gold | 1 | 2019 | 49 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 161 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2020 | 242 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2021 | 619 | 0.040 |
Why?
|
| Carbon | 1 | 2019 | 90 | 0.040 |
Why?
|
| Vasculitis | 1 | 2019 | 49 | 0.040 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2018 | 5 | 0.040 |
Why?
|
| Pericarditis | 1 | 2019 | 41 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2021 | 414 | 0.040 |
Why?
|
| Time-Lapse Imaging | 1 | 2018 | 10 | 0.040 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2018 | 23 | 0.040 |
Why?
|
| Rodentia | 1 | 2018 | 46 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2020 | 195 | 0.040 |
Why?
|
| Embryo, Nonmammalian | 1 | 2018 | 141 | 0.040 |
Why?
|
| Angina Pectoris | 2 | 2008 | 57 | 0.040 |
Why?
|
| Myocarditis | 1 | 2019 | 119 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1099 | 0.040 |
Why?
|
| Light | 1 | 2018 | 175 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1714 | 0.040 |
Why?
|
| Morphogenesis | 1 | 2018 | 213 | 0.040 |
Why?
|
| Rats | 1 | 2024 | 3658 | 0.040 |
Why?
|
| Risk Factors | 3 | 2019 | 9868 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2018 | 170 | 0.040 |
Why?
|
| Tretinoin | 1 | 2016 | 117 | 0.030 |
Why?
|
| Kinetics | 1 | 2018 | 1316 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2018 | 597 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 2541 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 350 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 758 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2016 | 316 | 0.030 |
Why?
|
| Cross Circulation | 1 | 2014 | 5 | 0.030 |
Why?
|
| Receptor, TIE-2 | 1 | 2014 | 13 | 0.030 |
Why?
|
| PAX3 Transcription Factor | 1 | 2014 | 27 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2016 | 307 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2014 | 75 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2793 | 0.030 |
Why?
|
| Reoperation | 2 | 2008 | 807 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2008 | 1025 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2014 | 122 | 0.030 |
Why?
|
| Sulfur Radioisotopes | 1 | 1993 | 9 | 0.030 |
Why?
|
| Oxyquinoline | 1 | 1993 | 5 | 0.030 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 1993 | 17 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 1993 | 102 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2014 | 261 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1993 | 152 | 0.030 |
Why?
|
| Glutamyl Aminopeptidase | 1 | 2012 | 3 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1993 | 401 | 0.030 |
Why?
|
| Methionine | 1 | 1993 | 102 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 421 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 58 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2012 | 123 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 386 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 673 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 231 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 1000 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 506 | 0.020 |
Why?
|
| Stroke | 2 | 2008 | 956 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1679 | 0.020 |
Why?
|
| Bacteria | 1 | 1993 | 482 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 1009 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2015 | 970 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 87 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2832 | 0.020 |
Why?
|
| Computational Biology | 1 | 2011 | 793 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2008 | 303 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 1857 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2006 | 113 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2006 | 120 | 0.020 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2006 | 122 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2006 | 196 | 0.010 |
Why?
|
| Pacemaker, Artificial | 1 | 2006 | 170 | 0.010 |
Why?
|
| History, 21st Century | 1 | 2004 | 269 | 0.010 |
Why?
|
| Forecasting | 1 | 2004 | 350 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2004 | 383 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 1272 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 1234 | 0.010 |
Why?
|
| Survival Rate | 1 | 2007 | 2001 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2006 | 583 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 2004 | 665 | 0.010 |
Why?
|
| Heart Valve Prosthesis | 1 | 2004 | 293 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2006 | 964 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 4648 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2006 | 784 | 0.010 |
Why?
|